William Aird/X
Sep 17, 2025, 10:54
Mitapivat Boosts ATP in Red Cells: Dr. William Aird on New Hope for Hemolytic Disorder
William Aird, Professor of Medicine at Harvard Medical School, posted on X:
”POWERING UP RBCs
Mitapivat is an oral allosteric activator of pyruvate kinase → ↑ glycolytic ATP.
FDA-approved for PK deficiency anemia; in trials for sickle cell disease and thalassemia.
More ATP = healthier, longer-lived red cells across hemolytic disorders.”
Stay updated with Hemostasis Today.
-
Jun 9, 2026, 15:34Shanon Marie Corsino: Nationwide Insights into Cancer-Associated Thrombosis in Filipino Patients
-
Jun 9, 2026, 15:20Murtuza Ali: Types of Blood Transfusions – A Quick Clinical Guide
-
Jun 9, 2026, 15:18Mital Jhaveri: TRACK Trial Findings Highlight the Unique Challenges of Advanced CKD
-
Jun 9, 2026, 14:56Mohamed Adel: Nursing Management of Patients with Thrombocytopenia
-
Jun 9, 2026, 14:31Mike Doss: The Critical Role of EMS in Preventing the Trauma Triad of Death
-
Jun 9, 2026, 14:13Kayla Garrett: Reducing False Positives and Improving Accuracy in APS
-
Jun 9, 2026, 14:07The Science Behind Bleeding Diathesis and Coagulation Defects – ICHCC
-
Jun 9, 2026, 13:58Kanchi Jain: Delivering Equitable Surgical Care for Women with Advanced Gynecologic Disease
-
Jun 9, 2026, 13:31Mboglen Diane: Why ATLS 11 Places Hemorrhage Control Before Airway Management